SCHEMBL6570360

SCHEMBL6570360

CCCO[C@H](C(=O)O)[C@@H](C[C@@H]1CCc2ccccc2C1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.42
FCER2 P06734 2/20 0.42
MMP9 P14780 2/20 0.42
MMP3 P08254 1/20 0.42
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
UGCG Q16739 1/20 0.38
PREP P48147 4/20 0.37
OPRD1 P41143 1/20 0.37
TAOK1 Q7L7X3 2/20 0.36
TAOK3 Q9H2K8 2/20 0.36
HTR1A P08908 1/20 0.36
PTGIR P43119 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27572977 1.00 MMP1 (0.42) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL6570364 1.00 MMP1 (0.42) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL6571500 0.91 MMP1 (0.42) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL6571559 0.83 MMP1 (0.40) MMP1FCER2MMP9MMP3ADRA1D
SCHEMBL6571554 0.83 MMP1 (0.40) MMP1FCER2MMP9MMP3ADRA1D
SCHEMBL27577603 0.83 MMP1 (0.40) MMP1FCER2MMP9MMP3ADRA1D
SCHEMBL6571517 0.79 MMP1 (0.52) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL6573689 0.79 MMP1 (0.52) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL7809851 0.79 MMP1 (0.52) MMP1FCER2MMP9MMP3MTNR1A
SCHEMBL6571514 0.79 MMP1 (0.52) MMP1FCER2MMP9MMP3MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1089963-B1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 2004-06-16 EP disclosed
US-6458779-B1 TREATMENT OF CONDITIONS ASSOCIATED WITH EXCESS PRODUCTION OF SOLUBLE CD23 (S-CD23) SUCH AS AUTOIMMUNE DISEASE AND ALLERGY. THE COMPOUNDS OF THE INVENTION ARE ALSO INHIBITORS OF THE RELEASE OF TUMOUR NECROSIS FACTOR (TNF). SMITHKLINE BEECHAM P.L.C. (GB) 2002-10-01 US disclosed
EP-1089963-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 2001-04-11 EP disclosed
WO-1999067201-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF THE PRODUCTION OF HUMAN CD23 AND OF THE TNF RELEASE SMITHKLINE BEECHAM PLC (GB) 1999-12-29 WO disclosed